In:
Urologia Internationalis, S. Karger AG, Vol. 106, No. 9 ( 2022), p. 909-913
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 The aim of this study was to evaluate the clinical value of 16 G biopsy needle in transperineal template-guided prostate biopsy (TTPB), compared with 18 G biopsy needle. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The patients who underwent TTPB from August 2020 to February 2021 were randomized into 2 groups using a random number table. The control group ( 〈 i 〉 n 〈 /i 〉 = 65) and the observation group ( 〈 i 〉 n 〈 /i 〉 = 58) performed biopsy with 18 G (Bard MC l820) and 16 G (Bard MC l616) biopsy needles, respectively. Positive rate of biopsy, Gleason score, complications, and pain score were statistically analyzed. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The age, prostate volume, PSA, and the number of cores were comparable between the 2 groups. The positive rate of biopsy in the observation group was 68.9% (40/58), meanwhile the control group was 46.2% (30/65). There was statistical difference between the 2 groups ( 〈 i 〉 p 〈 /i 〉 = 0.011). Gleason score of the observation group (8 [7–9]) was higher than that of the control group (8 [6–9] ) ( 〈 i 〉 p 〈 /i 〉 = 0.038). There was no significant difference in pain score and complications including hematuria, hematospermia, perineal hematoma, infection, and urinary retention between the 2 groups ( 〈 i 〉 p 〈 /i 〉 & #x3e; 0.05). 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 16 G biopsy needle significantly improved the positive rates and accurately evaluate the nature of lesions, meanwhile did not increase the incidence of complications compared with 18 G biopsy needle.
Type of Medium:
Online Resource
ISSN:
0042-1138
,
1423-0399
Language:
English
Publisher:
S. Karger AG
Publication Date:
2022
detail.hit.zdb_id:
1464417-4
Permalink